NextCure Net Debt vs Asset Turnover Analysis
NXTC Stock | USD 1.54 0.18 13.24% |
NextCure financial indicator trend analysis is infinitely more than just investigating NextCure recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether NextCure is a good investment. Please check the relationship between NextCure Net Debt and its Asset Turnover accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NextCure. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For information on how to trade NextCure Stock refer to our How to Trade NextCure Stock guide.
Net Debt vs Asset Turnover
Net Debt vs Asset Turnover Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of NextCure Net Debt account and Asset Turnover. At this time, the significance of the direction appears to have no relationship.
The correlation between NextCure's Net Debt and Asset Turnover is 0.07. Overlapping area represents the amount of variation of Net Debt that can explain the historical movement of Asset Turnover in the same time period over historical financial statements of NextCure, assuming nothing else is changed. The correlation between historical values of NextCure's Net Debt and Asset Turnover is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Debt of NextCure are associated (or correlated) with its Asset Turnover. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Asset Turnover has no effect on the direction of Net Debt i.e., NextCure's Net Debt and Asset Turnover go up and down completely randomly.
Correlation Coefficient | 0.07 |
Relationship Direction | Positive |
Relationship Strength | Insignificant |
Net Debt
The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.Asset Turnover
The ratio of net sales to average total assets, indicating how efficiently a company uses its assets to generate sales.Most indicators from NextCure's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into NextCure current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NextCure. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For information on how to trade NextCure Stock refer to our How to Trade NextCure Stock guide.The current year's Sales General And Administrative To Revenue is expected to grow to 1.25, whereas Selling General Administrative is forecasted to decline to about 14.9 M.
2021 | 2022 | 2023 | 2024 (projected) | Reconciled Depreciation | 7.2M | 4.1M | 3.9M | 3.7M | Total Operating Expenses | 70.8M | 75.9M | 67.6M | 56.6M |
NextCure fundamental ratios Correlations
Click cells to compare fundamentals
NextCure Account Relationship Matchups
High Positive Relationship
High Negative Relationship
NextCure fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 356.2M | 306.6M | 242.4M | 184.2M | 129.4M | 217.8M | |
Short Long Term Debt Total | 587K | 5.1M | 3.5M | 7.1M | 6.6M | 4.4M | |
Other Current Liab | 5.0M | 4.6M | 4.7M | 4.3M | 3.9M | 4.2M | |
Total Current Liabilities | 15.0M | 10.3M | 6.6M | 9.1M | 6.9M | 9.6M | |
Total Stockholder Equity | 321.5M | 293.7M | 233.4M | 167.5M | 114.4M | 166.4M | |
Other Liab | 16.3M | 792K | 2.4M | 899K | 809.1K | 768.6K | |
Net Tangible Assets | 321.5M | 293.7M | 233.4M | 167.5M | 192.7M | 173.2M | |
Property Plant And Equipment Net | 12.1M | 15.8M | 14.0M | 16.9M | 13.4M | 14.7M | |
Net Debt | (29.0M) | (29.3M) | (12.3M) | (19.5M) | (6.5M) | (6.8M) | |
Retained Earnings | (81.0M) | (117.6M) | (187.0M) | (261.8M) | (324.5M) | (308.3M) | |
Accounts Payable | 1.9M | 3.9M | 1.9M | 4.3M | 2.3M | 2.8M | |
Cash | 34.1M | 32.8M | 12.3M | 26.6M | 13.1M | 12.4M | |
Non Current Assets Total | 16.2M | 18.7M | 14.6M | 20.2M | 16.7M | 17.0M | |
Non Currrent Assets Other | 750K | 1.1M | 577K | 1.7M | 1.9M | 1.0M | |
Other Assets | 436K | 4.1M | 2.9M | 577K | 3.3M | 0.0 | |
Cash And Short Term Investments | 334.6M | 283.4M | 219.6M | 159.9M | 108.3M | 196.3M | |
Common Stock Shares Outstanding | 15.7M | 27.5M | 27.6M | 27.7M | 27.8M | 23.0M | |
Short Term Investments | 300.5M | 250.7M | 207.3M | 133.3M | 95.2M | 155.1M | |
Liabilities And Stockholders Equity | 356.2M | 306.6M | 242.4M | 184.2M | 129.4M | 217.8M | |
Non Current Liabilities Total | 19.6M | 2.6M | 2.4M | 7.5M | 8.1M | 7.7M | |
Capital Surpluse | 402.5M | 410.6M | 421.0M | 430.8M | 495.4M | 305.3M | |
Capital Lease Obligations | 127K | 135K | 0.0 | 7.1M | 6.6M | 6.9M | |
Other Current Assets | 3.7M | 2.8M | 8.2M | 4.1M | 3.6M | 3.6M | |
Other Stockholder Equity | 46.4M | 410.6M | 421.0M | 430.8M | 439.1M | 275.2M | |
Total Liab | 34.7M | 12.9M | 9M | 16.6M | 15.0M | 14.2M | |
Net Invested Capital | 326.5M | 297.2M | 233.4M | 167.5M | 114.4M | 168.0M | |
Property Plant And Equipment Gross | 12.1M | 15.8M | 26.7M | 33.5M | 33.7M | 22.5M | |
Total Current Assets | 340.0M | 288.0M | 227.8M | 164.0M | 112.7M | 200.8M | |
Accumulated Other Comprehensive Income | (38K) | 779K | (663K) | (1.5M) | (222K) | (233.1K) | |
Net Working Capital | 325.0M | 277.7M | 221.2M | 154.9M | 105.8M | 191.1M | |
Short Term Debt | 514K | 1.8M | 1.7M | 518K | 656K | 1.0M | |
Property Plant Equipment | 12.1M | 15.8M | 14.0M | 11.9M | 13.7M | 13.8M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether NextCure offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of NextCure's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Nextcure Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Nextcure Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NextCure. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For information on how to trade NextCure Stock refer to our How to Trade NextCure Stock guide.You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NextCure. If investors know NextCure will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NextCure listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.19) | Quarterly Revenue Growth (1.00) | Return On Assets (0.31) | Return On Equity (0.55) |
The market value of NextCure is measured differently than its book value, which is the value of NextCure that is recorded on the company's balance sheet. Investors also form their own opinion of NextCure's value that differs from its market value or its book value, called intrinsic value, which is NextCure's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NextCure's market value can be influenced by many factors that don't directly affect NextCure's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NextCure's value and its price as these two are different measures arrived at by different means. Investors typically determine if NextCure is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NextCure's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.